All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EU101
Therapeutic Area: Oncology Product Name: EU101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: National OncoVenture
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EU101
Therapeutic Area: Oncology Product Name: EU101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Samsung Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBT-176,Anti-EGFR antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
On IND clearance in South Korea, Bridge Biotherapeutics plans to initiate a dose escalation study as the first part of the phase I/II study in Korea to find the maximum tolerable dose of BBT-176.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Genome & Company which sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug receives FDA IND clearance for GEN-001,
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBT-176,Anti-EGFR antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2020
Details:
Bridge Biotherapeutics will start a dose escalation study as the 1st part of phase I/II study in Korea to find the maximum tolerated dose and to observe safety, and anti-tumor efficacy of BBT-176.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
